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A B S T R A C T
Epilepsy in those with learning disability (LD) is currently managed by various health agencies with no
obvious criteria for selecting particular care pathways and limited evidence-based descriptions of
optimal treatment. The aim of this study was to examine relationships between management strategies
and clinical outcomes in a community-based cohort of individuals with epilepsy and LD. The results may
inform epilepsy management directly and contribute to an evidence base to support development of
formal clinical trials.
An attempt was made to recruit all individuals with epilepsy and LD known to community LD health
services in one geographic area. However, those with profound LD were under-represented in the ﬁnal
sample. Information relating to the epilepsy, the severity of the LD, comorbidities and epilepsy
management were obtained retrospectively both from the clinical notes and from interviews with carers
and clinicians.
We recruited 183 individuals of whom 33% had no reported seizures in the previous three months
whilst 12% recorded more than 20 seizures per month. 73 individuals were receiving monotherapy, 66
were treated with two AEDs and 42 were prescribed three or more AEDs at the time of the study. In those
taking monotherapy, there was no difference in the mean monthly seizure frequency between groups
taking different AEDs. Similarly, for those prescribed two AEDS, no particular combinationwas associated
with signiﬁcantly lower seizure frequency. One third of the sample was receiving epilepsy management
from hospital neurology services but no criteria determining choice of treatment pathway were
identiﬁed. The ﬁndings suggest that more research needs to be carried out to identify both optimal care
pathways and AED strategies.
 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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The prevalence of learning disability in the general population
is reported as 3.7 per 1000 of the population.1 Epilepsy is common
in those with a learning disability (LD) and its frequency increases
progressively with more severe intellectual impairment. Overall
lifetime prevalence of epilepsy in those with mild to moderate
learning disability (IQ 35–70) has been estimated at 15% whilst in
thosewith severe to profound learning disability (IQ less than 50) a
prevalence of 30% has been reported.2 Prognosis for seizure control* Corresponding author. Tel.: +44 1223 746100 fax: +44 1223 746122.
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nb362@medschl.cam.ac.uk (N. Bateman), eiw20@medschl.cam.ac.uk (E. Williams),
steve.lindeman@cambsmh.nhs.uk (S. Lindeman), karenhimlok@gmail.com
(K. Himlok).
1059-1311/$ – see front matter  2008 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2008.10.009in people with learning disability and epilepsy has been poorer
than for those with epilepsy without learning disability.3 These
higher rates of inadequately controlled epilepsy bring increased
rates of morbidity and also mortality.4 In a Swedish study of over
1400 patients with learning disability, followed up for seven years,
the standardised mortality ratio (SMR) for those with learning
disability without epilepsy was 1.6 but the SMR increased to 5.0 in
those with concomitant epilepsy.5 Despite the fact that epilepsy is
a serious problem in those who have a learning disability, there is a
lack of randomised control trial evidence-based descriptions of
optimal treatment approaches in this clinical group.6,13 Within the
UK, epilepsy management in those with LD has been provided by
various combinations of primary care, specialist epilepsy and
neurology services as well as learning disability mental health
services and social care agencies, with no clear indications as to
which service provideswhat treatment to any particular individual
or why a particular care pathway was followed. The recentvier Ltd. All rights reserved.
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diagnosis and management of epilepsy (2004)6 stated that
‘‘qualitative and quantitative studies are needed to determine
the experience of individuals with learning disabilities and, in
particular, to compare outcomes for people with epilepsy and
learning disabilities managed by different groups of clinicians’’. In
the light of such a limited evidence base from which to establish
best practice for the management of epilepsy in those with a
learning disability there is a need to describe current treatment
practices and to consider the efﬁcacy of these. The aim of this study
was to collect this information from a community-based cohort of
individuals with epilepsy and LD and to examine the relationships
between management strategies and clinical outcomes. Such data
may contribute to the optimisation of epilepsymanagement in this
historically neglected clinical group with complex needs, both
directly and by providing an evidence base to inform the
development of formal clinical trials.
2. Method
With the support of the ﬁve Community LD Services covering
one county of England we attempted to recruit all patients with
epilepsy known to these services whether or not the epilepsy was
itself a focus of management by the learning disability teams. The
clinical teams, having identiﬁed all those with LD and epilepsy
known to the teams, then approached themand their carers, asking
if they would consider participating in this study. Capacity to
consent was supported by participants’ carers and use of visual
aids and sign language and those considered to lack capacity, even
with this support, were excluded from the study. The study was
approved by the local NHS Research Ethics Committee. Partici-
pants were only included when there was consensus amongst the
teams caring for them, based on clinical and sometimes EEG
evidence that they had a diagnosis of epilepsy. The participants
recruited do not represent an epidemiological sample but are
rather a selected majority within each of the involved clinical
services of individuals known to have LD and epilepsy.
Data were obtained retrospectively from participants’ clinical
notes. Data were also collected from interviews with carers, LD
team members, any neurology-based clinicians involved in their
management and General Practitioners. We collected data
describing each patient’s state over the preceding three months,
including current seizure types and frequency, the nature of the
clinical support and management received for the epilepsy,
including current antiepileptic drugs (AEDs), current or recent
co-morbid neurological and psychiatric pathologies and the nature
and severity of the LD.
3. Results
3.1. Population ascertained
Participants were recruited from the ﬁve locality-based
community adult LD services that covered one county of England
with a total population of 737,900 (Ofﬁce for National Statistics
www.statistics.gov.uk: Mid 2004 population estimates based on
the 2001 Census population). Out of 1487 individuals under the
care of these teams at the time of the study a total of 183
individuals provided data for this survey, representing 12% of all
the individuals with LD under the care of these teams and 71% of
the total number of individuals with epilepsy and LD identiﬁed by
the participating community LD teams as being under their care.
The mean age of the participants was 40 years with a range of 16–
72 years and 55% were male. The measure of the severity of the LD
of the participants was obtained from the community teams andwas based on their historical, functional and psychological
assessments. Of the study population, 20% had a mild LD (IQ
70–50), 16% amoderate (IQ 50–35), 57% a severe (IQ 35–20) and 7%
a profound (IQ < 20) LD. Considering the likely cause of the LD, this
was unclear in 61%. The most commonly ascribed speciﬁc causes
were cerebral palsy in 19% and a chromosomal disorder in 12%,
most commonly Down syndrome.
3.2. Description of epilepsy within the study population
The duration of diagnosed epilepsy extended from 1 to 71 years
with a mean of 26 years. Within the study population 75
individuals (41%) had epilepsy for at least 30 years. As expected,
a wide range of epilepsy syndromes were manifest by the
participants, with 39% described as having an idiopathic general-
ised epilepsy syndrome and 14% described as having symptomatic
or probably symptomatic focal epilepsy. However, in 47% of the
sample it was not possible to classify the nature of the epilepsy
syndrome. 46% of the study population had just one type of seizure
with the remainder being reported as having multiple seizure
types. Considering the frequency of epileptic seizures in the study
population, themean number of seizures permonthwas 15, with a
range of 0–559. Overall, 33% of individuals had no seizures in the
three months preceding data acquisition whilst 22 (12%) had
recorded an average of more than 20 seizures per month. Chi-
squared testing demonstrated that those with severe or profound
LD were more likely to have had at least 1 seizure in the three
months preceding the survey than those with less severe LD (Chi-
squared 12.2, df = 4, P = 0.016). There were no signiﬁcant
differences between the mean numbers of seizures per month
reported for those with idiopathic, focal or unclassiﬁed epilepsy.
Four participants were recorded as having more than 100 seizures
per month of whom two had myoclonic seizures, one had
myoclonic and absence seizures and one had absence seizures.
After excluding these four patients, the mean number of seizures
per month over the three months preceding the study was 7.2 (sd
14.1). Over the year preceding the study 85% of patients had no
recorded episodes of status epilepticus whilst 8% had one episode,
3% had two episodes and 4% had three or more episodes of status.
3.3. Relationships between seizure frequencies and different
antiepileptic drug regimens
The mean monthly seizure frequencies associated with
different antiepileptic drug (AED) regimens are listed in Table 1
for all those regimens prescribed to at least two participants. This
describes the ﬁndings from 137 individuals and excludes the data
from the four individuals who had more than 100 seizures per
month. Considering the study sample overall, two patients were
not taking any AEDs, 73 were receiving monotherapy, 66 were
being treatedwith two AEDs and 42were prescribed three ormore
AEDs at the time of the study.
i. There was no signiﬁcant difference between the numbers of
AEDs prescribed to those with idiopathic, focal or unclassiﬁed
epilepsy.
ii. As noted above, 33% of the study population had no seizures in
the three month period considered in the study. It can be seen
from Table 2 that each of the three most commonly prescribed
monotherapy regimens (carbamazepine, lamotrigine or sodium
valproate) was given in approximately equal proportions to
those with and without ongoing seizures.
iii. Considering the monotherapy regimens (Table 1), there was no
difference in mean monthly seizure frequency with respect to
which AED was prescribed (carbamazepine, lamotrigine,
Table 1
Mean monthly seizure frequencies associated with different antiepileptic drug regimens – for all regimens used in at least two individuals – (includes data from 137
individuals and excludes data from the 4 participants with >100 seizures per month).
AED regimen Number of times prescribed in sample Mean monthly seizure frequency sd
Carbamazepine 22 2.3 4.4
Carbamazepine + lamotrigine 8 6.6 6.6
Carbamazepine + topiramate 2 25.4 34.8
Carbamazepine + sodium valproate 18 6.9 12.1
Carbamazepine + clonazepam + sodium valproate 5 4.0 8.4
Carbamazepine + lamotrigine + sodium valproate 6 9.2 9.5
Lamotrigine 6 4.7 8
Lamotrigine + levetiracetam 3 20.7 23
Lamotrigine + sodium valproate 10 3.0 3.6
Levetiracetam + sodium valproate 3 5.4 5.6
Levetiracetam + sodium valproate + phenytoin 3 18.7 23.6
Phenobarbitone 2 0 0
Phenobarbitone + phenytoin 4 0.8 1.0
Phenytoin 3 0.3 0.5
Phenytoin + sodium valproate 4 6.0 6.6
Sodium valproate 39 4.1 15.0
Table 2
Number of prescriptions of speciﬁc AEDs regimens across the study population
prescribed to those with and without any seizures in the preceding three months.
AED treatment No seizures in
past 3 months
Any seizures in
past 3 months
CBZ 12 10
CBZ + LTG 1 7
CBZ + SVP 4 14
CBZ + LTG + SVP 0 6
CBZ + SVP + CLON 3 2
LTG 3 3
LTG + SVP 1 9
SVP 21 18
AED: antiepileptic drug; CBZ: carbamazepine; LTG: lamotrigine; SVP: sodium
valproate; CLON: clonazepam.
Table 3
Rates of individual AED prescription by neurology and LD services (as a percentage
of the number of participants seen in each service).
AED Neurology service LD service
Carbamazepine 38 49
Clobazam 7 1
Lamotrigine 29 17
Levetiracetam 7 7
Phenobarbitone 3 9
Phenytoin 9 12
Topiramate 0 2
Valproate 43 70
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metric Kruskal Wallis test P = 0.741).
iv. Those receiving monotherapy tended to have a lower mean
number of seizures per month than those prescribed two AEDs
(3.1 (sd 11.4) versus 6.6 (sd 11.6)) but this difference did not
reach signiﬁcance (t = 1.8, P = 0.077).
v. Considering those prescribed two AEDS (as listed in Table 1), no
particular combination was associated with signiﬁcantly lower
seizure frequency than any other (non-parametric Kruskal
Wallis test P = 0.512).
4. Delivery of epilepsy health care
4.1. Agencies involved
In the United Kingdom medical care of epilepsy in patients
with a learning disability is generally available from one or more
of the following parts of the National Health Service; the patient’s
GP, the local Learning Disability Psychiatry team, and hospital-
based neurology services. Of the patients surveyed, all of whom
were ascertained on the basis of being under the care of a
community Learning Disability Team for management of their
LD, but not necessarily of their epilepsy, 37% received epilepsy
care from a hospital-based neurology service. The patients’ GP
also actively contributed to their epilepsy care, in terms of
initiating or changing treatments, in 63% of cases and for 6% of
participants the GP was the only clinician supporting the
epilepsy treatment.4.2. Do epilepsy characteristics vary according to the services
accessed?
Excluding the four patients with the greatest number of
seizures, who were all seeing GP, LD and neurology services, it was
observed that mean seizure frequency was not signiﬁcantly
different in those who were receiving epilepsy care from hospital
neurology services (6.5 seizures/month) compared to those who
were not (8.5 seizures/month, P = 0.358). Neither were there
signiﬁcant differences in mean duration of epilepsy (24 years
versus 27 years) or number of different seizure types (1.6 in both
instances) between those who did or did not receive neurology
service management. There was, however, a signiﬁcant difference
between the mean number of AEDs prescribed to those whose
epilepsy was only managed by LD services (1.7 AEDs) and those
who also received Neurology service input (2.14 AEDs) (t = 3.257,
P = 0.001). Considering the frequency with which neurology
services compared to LD services prescribed individual agents, it
was noted that clobazam was prescribed relatively more
frequently to those receiving neurology-based AED management
(x2 6.627, df = 1, P = 0.018), whilst sodium valproate was
prescribed relatively less often (x2 5.027, df = 1, P = 0.025). The
other AEDs listed in Table 3 were prescribed at approximately
similar rates in LD and neurology services.
4.3. Do LD characteristics vary according to the services accessed?
There was no evidence that differences in severity of LD
contributed to whether or not neurology services were involved in
patients’ epilepsy care. It was observed that similar proportions, of
approximately one third, of both those with mild to moderate and
Table 4
Distribution of psychopathological symptoms according to service attended.
Psychopathology Neurology attendees.
Percentage of those
attending neurology
LD (GP) attendees.
Percentage of those attending
LD but not neurology
Depression 32 18
Psychosis 6 14
Challenging behaviour 7 17
Self-injury 4 2
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neurology services.
4.4. Do comorbid psychopathology characteristics vary according to
the services accessed?
A full description of the psychopathology observed in the
participants reported in the current account is presented else-
where.7 In the current paper we address the question of whether
the presence of ongoing psychiatric symptomatology affected
which treating agencies participants were seeing. The prevalence
of comorbid psychopathology was compared between those who
were and those who were not receiving neurology services and it
was observed that there were similar rates of psychopathology, of
37%, in both groups. When looking at the distribution of the four
most common psychopathological presentations; depression,
psychotic symptoms, challenging behaviour and self-injury
(Table 4), Chi-square analysis demonstrated a strong trend for
depression to be seen more often than expected in those attending
neurology services (x2 = 3.583, df = 1, P = 0.058) and a somewhat
weaker trend for challenging behaviour to be seenmore often than
expected in those attending LD services (x2 = 3.075, df = 1,
P = 0.079). Those with psychotic symptoms or self-injury were
not relatively over-represented amongst either Neurology clinic or
LD service attendees.
4.5. Do comorbid neurological conditions vary according to the
services accessed?
As described above, participants were noted to have been
diagnosed with a range of neurological conditions, the commonest
speciﬁc diagnoses being cerebral palsy, dementia and hydro-
cephalus. However, it was found that 29% of those with and 34% of
those without a comorbid neurological diagnosis were being
treated by neurology services, demonstrating that presence of an
additional neurological condition was not a factor in determining
which treating agencies were involved in providing care at the
time of the study.
5. Discussion
This study presents three main groups of ﬁndings from a
community-based study of people with epilepsy and a learning
disability. First, as has previously been reported, those with LD and
epilepsy tend to have relatively poorly controlled seizures. Second,
careful analysis of the varying AED regimens prescribed does not
indicate that any particular regimen is more efﬁcacious than any
other, across the overall study sample, in reducing seizure
frequency. As discussed below however, this similarity in apparent
efﬁcacy may have arisen from the fact that this patient group were
already largely treatment-refractory at the time of their entry into
the study. Third, whilst approximately one third of the sample
were receiving epilepsy management from hospital-based neurol-
ogy services at the time of the study, it was not clear what factors
determined which treatment pathway individual patients fol-
lowed. Each of these ﬁndings will be considered in turn.
In our study sample 67% reported ongoing seizures, which is
very close to the comparable ﬁgure of 68% reported by McGrother
et al.8 Similarly, our ﬁnding of 33% with no seizures in the three
months preceding our study is also close to the ﬁgure of 37%
seizure freedom reported by Huber et al.9 The rates of seizure-
freedom observed in the current study of people with LD are
hence consistent with previous studies and are considerably less
than the 50–65% seizure freedom rate expected in the general
population.10,11Although it is clear that epilepsy within the learning-disabled
population is common and difﬁcult to treat, a recent Cochrane
review identiﬁed just 12 adequate trials reporting 761 partici-
pants,12 concluding that the area was under-investigated and that
it was not possible to comment on relative efﬁcacy between
medications, making treatment decisions difﬁcult. A long-term
retrospective study of AED efﬁcacy on a group of people with
epilepsy and LD resident in a large epilepsy centre13 also noted that
no speciﬁc regimen was clearly superior across the whole range of
affected individuals. That account did however suggest that the
combination of sodium valproate with lamotriginemay be a useful
innovation. In the current study no particular regimen was
associated with increased rates of seizure freedom. Because many
of the patients in this study had a long history of uncontrolled
epilepsy, those treated with the newer antiepileptic drugs will, in
many cases, have been those who had already failed treatment
with more established antiepileptic drugs and those who were
treated with polytherapy will also have been a more resistant
group. Consequently, the frequency of the seizures in those treated
with more recently introduced AEDs may be more a reﬂection of
the difﬁculty in treating the epilepsy and the use of these agents as
second or third line therapies than an indication of the general
efﬁcacy (or lack of efﬁcacy) of speciﬁc agents. Only around a third
of the participants were maintained on monotherapy and neither
monotherapy with carbamazepine, lamotrigine nor sodium
valproate nor the combination of lamotrigine and sodium
valproate conferred any signiﬁcant advantage in terms of reduced
seizure frequency. Whilst the monotherapy regimens were
associated with the lowest seizure frequencies, this was pre-
dictable and is likely to have been because those whose epilepsy
was most readily controlled were able to be maintained without
the clinically perceived need to add in an additional AED.
Considering the overall pattern of AED utilization, this has
previously been considered byMoran et al.11 in a population-based
sample that included those with and without LD, although the
relative proportions of these two groups were not reported. In the
people investigated in the current study, who all had LD, there
were some similarities and some differences in AED utilization
compared to that wider survey. In common with those authors we
noted that sodium valproate and carbamazepine were the most
commonly prescribed agents as well as the most commonly
prescribed as monotherapy. However, overall in the current LD
sample monotherapy was used less often: in 40% compared to 69%
in that wider population. In the current study however, whilst 43%
of the participants had been diagnosedwith epilepsy for at least 17
years, predating all AEDs introduced after lamotrigine, only 4% of
monotherapy prescriptions were for phenytoin with 3% for
phenobarbital. The comparable ﬁgures reported by Moran et al.
were 24% for phenytoin and 5% for phenobarbital. These results
suggest that over the years the pharmacological management of
epilepsy in people with LD has been modiﬁed according to
emerging changes in clinical practice recommendations.
In addition to the question of which AEDs may be most usefully
prescribed to this clinical group the issue of whether different care
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remains unresolved. Although in principle it might be predicted
that some patients would be better served by one care pathway
whilst othersmight be better served by an alternative, this was not
apparent in the current study. The evidence from this study
suggests that there are currently no obvious criteria for determin-
ing whether the epilepsy in any particular individual with LD is
managed either by the community LD team or by more specialist
neurology services. Obvious factors, such as markers of epilepsy
severity or the nature of associated comorbidities do not appear to
play a role. However, the ﬁndings that on average more AEDs are
prescribed by neurology services and that these services are also
more likely to prescribe clobazam – often used as an adjunct in
difﬁcult to control clusters of seizures – suggests that those
referred to neurology services may at one time have had more
severe epilepsy than those treated by LD services. Unfortunately,
the cross-sectional design of the study does not allow this
possibility to be further explored. It is interesting to note though
that at the time the study was carried out there were similar mean
seizure frequencies across these two care pathways (of respec-
tively 6.5 and 8.5 seizures/month). Thismay suggest that any of the
current management approaches in this clinical group are unlikely
to be able to achieve signiﬁcantly better overall seizure control
than this within the LD population. This observation is supported
by the audit presented by Scheepers et al.14 which reported that
the effect of a careful treatment review in a comparable population
brought the mean monthly seizure frequency down to 5.9, with
27% becoming seizure-free compared to 33% in the current study.
Historically, (as noted in the UK Government White Paper—
‘Valuing People’)15 those with a learning disability have had
difﬁculty in accessing the specialist health services available to the
general population. Whilst in the LD population described in the
current study those with more severe LD did not access specialist
neurology services any less often that those with milder levels of
disability, it was the case that more than 60% of individuals had
their ongoing epilepsy care provided by community LD services. In
the absence of clear care pathways for individuals into either of
these treatment approaches, and the similar seizure frequency in
both these treatment groups, it is not possible to determine
whether those with LD are being disadvantaged in regard to their
access to specialist neurology services.
In drawing the above conclusions, several limitations to this
study should be kept in mind. Overall, the study identiﬁed that an
average of 17% of those under the care of LD health teams within
the surveyed areas had epilepsy. This is a smaller percentage than
the overall prevalence of epilepsy reported in the LD population, of
25% upwards. The study sample is not an epidemiological sample
of those with LD and epilepsy. One reason for this is that responses
from those with profound LD, in whom there are higher rates of
epilepsy, were under-represented due to the inability to obtain
consent from the great majority of this group. With respect to the
interpretation of results associated with different AED regimens,
because of the small numbers of prescriptions for the newest AEDs
and because many of the participants had refractory epilepsy, it is
not possible to draw conclusions regarding the usage patterns and
likely efﬁcacy of these agents.
The data reported here highlight several potential difﬁculties
that need to be overcome in the development of randomisedcontrolled trials of AEDs in those with epilepsy and LD. These
include problems in identifying the epilepsy syndrome, the long
duration of epilepsy, in many cases, prior to recruitment into a
study of adults and the likelihood of a wide range of neurological
and psychiatric comorbidities. However, it is not just the question
of which AEDs may be most usefully prescribed to this clinical
group that remains unresolved but also the issue of whether
different care pathways would be more useful for different clinical
presentations.
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